Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | The latest advances in CAR-T therapy for B-ALL

Peihua Lu • 1 Jun 2021
EHA 2021
Acute Lymphoblastic Leukemia Leukemia CAR-T Lenalidomide Navitoclax

Peihua Lu, MD, Lu Daopei Hospital, Langfang, China and Lu Daopei Institute of Hematology, Beijing, China, gives an overview of the latest advances in chimeric antigen receptor T-cell (CAR-T) therapy for patients with B-cell acute lymphoblastic leukemia (B-ALL), in particular highlighting research into universal CARs which could help to reduce the cost of CAR-T therapy, and novel combinations of CAR-T. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Peihua Lu

AlloSCT outcomes in patients who achieve CR with CAR-T versus chemotherapy in T-ALL/LBL
1:15
AlloSCT outcomes in patients who achieve CR with CAR-T versus chemotherapy in T-ALL/LBL
Peihua Lu • 9 Dec 2023
Anti-CD7 CAR-T therapy for T-ALL/LBL
0:53
Anti-CD7 CAR-T therapy for T-ALL/LBL
Peihua Lu • 9 Dec 2023
CD-7 targeted CAR-T therapy in heavily pretreated patients with AML: a Phase I trial
3:16
CD-7 targeted CAR-T therapy in heavily pretreated patients with AML: a Phase I trial
Peihua Lu • 9 Dec 2023
Evaluating the safety and efficacy of novel anti-CD7 universal CAR-T therapy in R/R T-ALL and T-LBL
2:16
Evaluating the safety and efficacy of novel anti-CD7 universal CAR-T therapy in R/R T-ALL and T-LBL
Peihua Lu • 12 Dec 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals